Table 6 Diagnostic value of ANXA3 in predicting glucocorticoid response in patients with HBV-ACLF.
Parameters | Sensitivity (%) | Specificity (%) | Youden index | AUC | Cut-off | 95% CI |
|---|---|---|---|---|---|---|
Primary endpoint | ||||||
MELD score | 62.86 | 84.93 | 0.48 | 0.79 | 22.43 | 0.71 to 0.89 |
PMR (ANXA3) | 80 | 89.40 | 0.69 | 0.88 | 9.54 | 0.82 to 0.95 |
mRNA (ANXA3) | 82.86 | 78.08 | 0.61 | 0.83 | 0.87 | 0.74 to 0.92 |
MELD score + PMR (ANXA3) | 82.86 | 83.56 | 0.66 | 0.89 | −0.67 | 0.83 to 0.95 |
Secondary endpoints | ||||||
PMR (ANXA3)-TBIL | 66.67 | 84.13 | 0.51 | 0.79 | 13.45 | 0.70 to 0.87 |
PMR (ANXA3)-PTA | 84.62 | 65.22 | 0.50 | 0.81 | 10.81 | 0.72 to 0.89 |
PMR (ANXA3)-MELD score | 70 | 83.54 | 0.54 | 0.82 | 13.03 | 0.75 to 0.90 |
PMR (ANXA3)-ACLF grade | 93.02 | 62.26 | 0.55 | 0.84 | 9.45 | 0.76 to 0.91 |
PMR (ANXA3)-HE | 73.63 | 83.33 | 0.57 | 0.82 | 9.57 | 0.63 to 0.99 |
PMR (ANXA3)-ascites | 86.96 | 62.50 | 0.49 | 0.83 | 9.95 | 0.73 to 0.93 |
